Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma

HPB

Volumn 14, Issue 9, 2012, Pages 573-582

  Nagano, Motoaki ^a   Hatakeyama, Kinta ^a   Kai, Masahiro ^a   Nakamura, Hajime ^b   Yodoi, Junji ^b   Asada, Yujiro ^a   Chijiiwa, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

THIOREDOXIN 1; THIOREDOXIN REDUCTASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CELL NUCLEUS; CHOLELITHIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 84865120005     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00482.x     Document Type: Article

References (46)

1. Kai M, Chijiiwa K, Ohuchida J, Nagano M, Hiyoshi M, Kondo K,. (2007) A curative resection improves the postoperative survival rate even in patients with advanced gallbladder carcinoma. J Gastrointest Surg 11: 1025-1132.
2. Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nakagawa T,. (2009) Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16: 1-7.
3. Kokudo N, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, et al. (2003) Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg 138: 741-150.
4. Butte J, Matsuo K, Gonen M, D'Angelica M, Waugh E, Allen P, et al. (2011) Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212: 50-61.
5. Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, et al. (2011) Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29: 4627-4632.
6. Chijiiwa K, Nakano K, Ueda J, Noshiro H, Nagai E, Yamaguchi K, et al. (2001) Surgical treatment of patients with T2 gallbladder carcinoma invading the subserosal layer. J Am Coll Surg 192: 600-607. (Pubitemid 32422237)
7. Chijiiwa K, Kai M, Nagano M, Hiyoshi M, Ohuchida J, Kondo K,. (2007) Outcome of radical surgery for stage IV gallbladder carcinoma. J Hepatobiliary Pancreat Surg 14: 345-350. (Pubitemid 47190053)
8. Nakamura H, Nakamura K, Yodoi J,. (1997) Redox regulation of cellular activation. Annu Rev Immunol 15: 351-369. (Pubitemid 27169285)
9. Berndt C, Lillig CH, Holmgren A,. (2007) Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 292: 1227-1236.
10. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, et al. (1996) Enhanced coexpression of thioredoxin and high mobility group 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 56: 5330-5333. (Pubitemid 27011357)
11. Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, et al. (1996) Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97: 2268-2276.
12. Arnér ES, Holmgren A,. (2006) The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426. (Pubitemid 44780139)
13. Voehringer DW,. (1999) BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med 27: 945-950. (Pubitemid 29507468)
14. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM,. (1997) Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 272: 30615-30618. (Pubitemid 27527491)
15. Maulik N, Das DK,. (2002) Redox signaling in vascular angiogenesis. Free Radic Biol Med 33: 1047-1060.
16. Holmgren A,. (1985) Thioredoxin. Annu Rev Biochem 54: 237-271. (Pubitemid 15073647)
17. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J,. (1997) AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94: 3633-3638. (Pubitemid 27180424)
18. Gasdaska JR, Berggren M, Powis G,. (1995) Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 6: 1643-1650.
19. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM,. (2003) The thioredoxin- thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23: 2425-2433. (Pubitemid 36897112)
20. Welsh SJ, Bellamy WT, Briehl MM, Powis G,. (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095. (Pubitemid 34984438)
21. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, et al. (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142: 46-51. (Pubitemid 36934520)
22. Noike T, Miwa S, Soeda J, Kobayashi A, Miyagawa S,. (2008) Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer. Hum Pathol 39: 201-208.
23. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. (2001) Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7: 3087-3091. (Pubitemid 32963828)
24. Japanese Society of Biliary Surgery. (2003) General Rules for Surgical and Pathological Studies on Cancer of the Biliary Tract, 5th edn. Tokyo: Kanehara.
25. Burnette WN,. (1981) 'Western blotting': electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112: 195-203.
26. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik RK, Säily M, Koistinen P, et al. (2001) Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757. (Pubitemid 32708645)
27. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwang TS, Park EM, et al. (2003) Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 19: 285-298. (Pubitemid 38002149)
28. Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH,. (2007) Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13: 326-335. (Pubitemid 351287314)
29. Kawamoto T, Shoda J, Asano T, Ueda T, Furukawa M, Koike N, et al. (2002) Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 98: 427-434. (Pubitemid 34188686)
30. Powis G, Mustacich D, Coon A,. (2000) The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322.
31. Gasdaska PY, Oblong JE. Cotgreave IA, Powis G,. (1994) The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some tumors. Biochim Biophys Acta 1218: 292-296. (Pubitemid 24252524)
32. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, et al. (2005) High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11: 8425-8430. (Pubitemid 41746957)
33. Turunen N, Karihtala P, Mantyniemi A, Sormunen R, Holmgren A, Kinnula VL, et al. (2004) Thioredoxin is associated with proliferation, P53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 112: 123-132. (Pubitemid 38406686)
34. Yoon BI, Kim YH, Yi JY, Kang MS, Jang JJ, Joo KH, et al. (2010) Expression of thioredoxin during progression of hamster and human cholangiocarcinoma. Cancer Sci 101: 281-288.
35. Ueno M, Matsutani Y, Nakamura H, Masutani H, Yagi M, Yamashiro H, et al. (2000) Possible association of thioredoxin and p53 in breast cancer. Immunol Lett 75: 15-20.
36. Schroeder P, Popp R, Wiegand B, Altschmied J, Haendeler J,. (2007) Nuclear redox-signaling is essential for apoptosis inhibition in endothelial cells-important role for nuclear thioredoxin-1. Arterioscler Thromb Vasc Biol 27: 2325-2331. (Pubitemid 350203946)
37. Arai RJ, Masutani H, Yodoi J, Debbas V, Laurindo FR, Stern A, et al. (2006) Nitric oxide induces thioredoxin-1 nuclear translocation: possible association with the p21Ras survival pathway. Biochem Biophys Res Commun 348: 1254-1260. (Pubitemid 44291340)
38. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, et al. (2000) Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 60: 6688-6695.
39. Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma X, et al. (1999) Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21: 6317-6327.
40. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, et al. (1999) Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815. (Pubitemid 129512885)
41. Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R, et al. (2001) The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear β-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol 159: 1613-1617. (Pubitemid 33062503)
42. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. (2010) ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281.
43. Tonissen KF, Di Trapani G,. (2009) Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 53: 87-103.
44. Sun Y, Rigas B,. (2008) The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 68: 8269-8277.
45. Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, et al. (2007) A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13: 2109-2114. (Pubitemid 46649879)
46. Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, et al. (2011) A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 67: 503-509.